Literature DB >> 28275625

Antibody darts on target for acute myelogenous leukemia.

A John Barrett1.   

Abstract

Entities:  

Year:  2017        PMID： 28275625      PMCID： PMC5337213          DOI： 10.21037/atm.2017.01.54

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  25 in total

1.  High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study.

Authors:  François Vergez; Alexa S Green; Jerome Tamburini; Jean-Emmanuel Sarry; Baptiste Gaillard; Pascale Cornillet-Lefebvre; Melanie Pannetier; Aymeric Neyret; Nicolas Chapuis; Norbert Ifrah; François Dreyfus; Stéphane Manenti; Cecile Demur; Eric Delabesse; Catherine Lacombe; Patrick Mayeux; Didier Bouscary; Christian Recher; Valerie Bardet
Journal:  Haematologica       Date:  2011-09-20       Impact factor: 9.941

Review 2.  Harnessing the immune system in acute myeloid leukaemia.

Authors:  Rebecca Austin; Mark J Smyth; Steven W Lane
Journal:  Crit Rev Oncol Hematol       Date:  2016-05-11       Impact factor: 6.312

Review 3.  Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence.

Authors:  Koen van Besien
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

4.  A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: preclinical activity and safety in nonhuman primates.

Authors:  Gurunadh R Chichili; Ling Huang; Hua Li; Steve Burke; Leilei He; Qin Tang; Linda Jin; Sergey Gorlatov; Valentina Ciccarone; Francine Chen; Scott Koenig; Michele Shannon; Ralph Alderson; Paul A Moore; Syd Johnson; Ezio Bonvini
Journal:  Sci Transl Med       Date:  2015-05-27       Impact factor: 17.956

5.  Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.

Authors:  Qifang Zhang; Dewan Md Sakib Hossain; Priyanka Duttagupta; Dayson Moreira; Xingli Zhao; Haejung Won; Ralf Buettner; Sergey Nechaev; Marcin Majka; Bin Zhang; Qi Cai; Piotr Swiderski; Ya-Huei Kuo; Stephen Forman; Guido Marcucci; Marcin Kortylewski
Journal:  Blood       Date:  2016-01-21       Impact factor: 22.113

6.  Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.

Authors:  Saar Gill; Sarah K Tasian; Marco Ruella; Olga Shestova; Yong Li; David L Porter; Martin Carroll; Gwenn Danet-Desnoyers; John Scholler; Stephan A Grupp; Carl H June; Michael Kalos
Journal:  Blood       Date:  2014-03-04       Impact factor: 22.113

Review 7.  Novel immunotherapies in lymphoid malignancies.

Authors:  Connie Lee Batlevi; Eri Matsuki; Renier J Brentjens; Anas Younes
Journal:  Nat Rev Clin Oncol       Date:  2015-11-03       Impact factor: 66.675

Review 8.  Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic).

Authors:  Kazusa Ishii; Austin J Barrett
Journal:  Ther Adv Hematol       Date:  2016-02

Review 9.  Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1?

Authors:  Laura E Finn; James M Foran
Journal:  Curr Opin Hematol       Date:  2016-03       Impact factor: 3.284

Review 10.  'Acute myeloid leukemia: a comprehensive review and 2016 update'.

Authors:  I De Kouchkovsky; M Abdul-Hay
Journal:  Blood Cancer J       Date:  2016-07-01       Impact factor: 11.037
View more
  1 in total

1.  41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo.

Authors:  Matteo Libero Baroni; Diego Sanchez Martinez; Francisco Gutierrez Aguera; Heleia Roca Ho; Maria Castella; Samanta Romina Zanetti; Talia Velasco Hernandez; Rafael Diaz de la Guardia; Julio Castaño; Eduardo Anguita; Susana Vives; Josep Nomdedeu; Helene Lapillone; Anne E Bras; Vincent H J van der Velden; Jordi Junca; Pedro Marin; Alex Bataller; Jordi Esteve; Binje Vick; Irmela Jeremias; Angel Lopez; Marc Sorigue; Clara Bueno; Pablo Menendez
Journal:  J Immunother Cancer       Date:  2020-06       Impact factor: 13.751
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.